Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05809934 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT05809934 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 220 participants.
The verdict
NCT05809934, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M Risk Allele
Interventions
- OTHER Placebo
- DRUG AZD2693
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2025-09-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05809934
The ClinicalTrials.gov registry entry for NCT05809934 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05809934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05809934 about?
NCT05809934 is a clinical study titled "A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis". A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M Risk Allele
What is the current status of trial NCT05809934?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2023-03-15. Estimated completion is 2025-09-29.
What interventions are being tested in trial NCT05809934?
The interventions under investigation include: Placebo (OTHER), AZD2693 (DRUG).
Who is sponsoring clinical trial NCT05809934?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.